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A 9-year-old female was referred to Genetics with the possible
dual diagnoses of 3p deletion and 9p duplication syndromes
based on a chromosomal microarray (CMA) report of an unbalanced chromosomal translocation resulting in 3p deletion
and 9p duplication.
She was the first child born to non-consanguineous German
parents with an unremarkable family history. Her mother had
well-controlled type 1 diabetes throughout pregnancy. Our
patient was delivered at 38 weeks via caesarean section with
a birth weight of 3.28 kg. The perinatal course was otherwise
unremarkable.
By 7 years of life, she had a history of poor growth due to feeding difficulties. The CMA was requested by her paediatrician
as part of initial blood tests to investigate her poor growth. All
other tests were normal. She underwent adenoidectomy after
which her growth parameters improved.
Her CMA showed a 4 Mb terminal loss of 3p26.3–p26.1
which included the four OMIM morbid genes (CHL1, CNTN6,
CNTN4, and CRBN) implicated in the characteristic features
of 3p deletion. In addition, there was a 4.4 Mb 9p24.1–p24.3
duplication, previously reported in individuals with autism and
cognitive delays.
When she presented to Genetics, her growth parameters
were all above the fifth percentile. The patient had good overall
health, no systemic anomalies, and no dysmorphic features. She
had normal development and was performing well at school.
Her mother was later confirmed to have the same CMA finding.
3p deletions and 9p duplications can each lead to recognizable syndromes characterized by developmental delay, autism,

and distinct dysmorphic features (1,2). However, neither the
patient nor her mother had any dysmorphisms or clinical signs
suggestive of either syndrome. There have been reports of normal or minimal phenotypes found in patients with a 3p deletion
or 9p duplication, but not both in the same patient; our case is
certainly unusual, but given the normal phenotype, the findings
are likely incidental.
By the time that our patient presented to Genetics, her
growth parameters were within normal limits, which would
not have qualified her for a CMA test. Follow-up parental
studies confirmed that the copy number variants (CNVs)
were maternal in origin. The patient’s mother had wellcontrolled type 1 diabetes without anomalies or health
concerns. We were able to research the literature for similar
cases of normal phenotype associated with these changes
(1,3,4). The family was reassured after viewing these reports.
In such cases of discrepancy between cytogenetic findings
and clinical presentation, a close collaboration between the
paediatrician and genetic team is paramount to best counsel
the patient’s family.
While CMA is a powerful diagnostic tool, it should be ordered under appropriate clinical indications. In Ontario, Ministry
of Health-funded CMA requires one of two indications: developmental delay and/or a minimum of two congenital anomalies. The list of those physical anomalies is broad and may range
from major to minor birth defects. Paediatricians are now more
aware of genetic testing and are proactive in requesting CMA for
patients who meet the minimum criteria. Our patient initially
presented with growth parameters below the third percentile
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for age, which met testing criteria. CMA was ordered as a routine ‘screen’ test as opposed to a diagnostic test. The family was
unaware of the nature of the genetic test that was performed as
part of routine blood work. Limitations of the test and potential
outcomes (such as incidental findings [IFs], variants of uncertain clinical significance) were not discussed. The pathogenic
change was concerning to both the referring paediatrician and
the patient’s family as it gave the patient a dual diagnosis, which
she clearly did not have.
Our case illustrates many challenges of genetic testing, specifically test indications, informed consent, IFs, and result
interpretation.
As a pangenomic test, CMA can identify CNVs that are IFs.
IFs can cause significant parental anxiety and label patients
with diagnoses they do not have. Pre-test counselling should
be routinely performed prior to genetic testing; physicians
need to educate patients on the risk of IFs and obtain informed consent. Current evidence shows that this is not routine
practice (5,6). Interpretations of IFs can be equally challenging
for physicians—many report uncertainties returning IF results
to patients, which has ethical implications (5). This is further
complicated by a lack of standardized training in genetics for
paediatricians.
In summary, our case provides several important tips for
paediatricians: choose CMA judiciously under proper indications, provide pre-test counselling including the risk of IFs and
obtain informed consent, interpret reports with caution, utilize
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available genetic education resources, and refer to Genetics
when further evaluation is needed.
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